SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Maximilian Bockhorn, Faik G. Uzunoglu, Mustapha Adham, Clem Imrie, Miroslav Milicevic, Aken A. Sandberg, Horacio J. Asbun, Claudio Bassi, Markus Büchler, Richard M. Charnley, Kevin Conlon, Laureano Fernandez Cruz, Christos Dervenis, Abe Fingerhutt, Helmut Friess, Dirk J. Gouma, Werner Hartwig, Keith D. Lillemoe, Marco Montorsi, John P. Neoptolemos, Shailesh V. Shrikhande, Kyoichi Takaori, William Traverso, Yogesh K. Vashist, Charles Vollmer, Charles J. Yeo, Jakob R. Izbicki, Borderline resectable pancreatic cancer A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS), Surgery, 2014,

    CrossRef

  2. 2
    Matthew H.G. Katz, Christopher H. Crane, Gauri Varadhachary, Management of Borderline Resectable Pancreatic Cancer, Seminars in Radiation Oncology, 2014, 24, 2, 105

    CrossRef

  3. 3
    Rebekah R. White, Douglas B. Evans, Neoadjuvant Chemotherapy for Localized Pancreatic Cancer: Too Little or Too Long?, Annals of Surgical Oncology, 2014, 21, 5, 1508

    CrossRef

  4. 4
    S Boeck, M Haas, S Ormanns, S Kruger, J T Siveke, V Heinemann, Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult, British Journal of Cancer, 2014,

    CrossRef

  5. 5
    Sarah Hoffe, Nikhil Rao, Ravi Shridhar, Neoadjuvant vs Adjuvant Therapy for Resectable Pancreatic Cancer: The Evolving Role of Radiation, Seminars in Radiation Oncology, 2014, 24, 2, 113

    CrossRef

  6. 6
    Joseph M. Herman, Pancreaticobiliary Malignancies: Past, Present, and Future, Seminars in Radiation Oncology, 2014, 24, 2, 61

    CrossRef

  7. 7
    Nestor F. Esnaola, Uzair B. Chaudhary, Paul O'Brien, Elizabeth Garrett-Mayer, E. Ramsay Camp, Melanie B. Thomas, David J. Cole, Alberto J. Montero, Brenda J. Hoffman, Joseph Romagnuolo, Kelly P. Orwat, David T. Marshall, Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer, International Journal of Radiation Oncology*Biology*Physics, 2014, 88, 4, 837

    CrossRef

  8. 8
    Hop S. Tran Cao, Alpana Balachandran, Huamin Wang, Graciela M. Nogueras-González, Christina E. Bailey, Jeffrey E. Lee, Peter W. T. Pisters, Douglas B. Evans, Gauri Varadhachary, Christopher H. Crane, Thomas A. Aloia, Jean-Nicolas Vauthey, Jason B. Fleming, Matthew H. G. Katz, Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer, Journal of Gastrointestinal Surgery, 2014, 18, 2, 269

    CrossRef

  9. 9
    Daniel M. Halperin, Gauri R. Varadhachary, Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?, Current Oncology Reports, 2014, 16, 2

    CrossRef

  10. 10
    Ching-Wei D. Tzeng, Aparna Balachandran, Mediha Ahmad, Jeffrey E. Lee, Sunil Krishnan, Huamin Wang, Christopher H. Crane, Robert A. Wolff, Gauri R. Varadhachary, Peter W. T. Pisters, Thomas A. Aloia, Jean-Nicolas Vauthey, Jason B. Fleming, Matthew H. G. Katz, Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer, HPB, 2014, 16, 4
  11. 11
    Ching-Wei D. Tzeng, Hop S. Tran Cao, Jeffrey E. Lee, Peter W. T. Pisters, Gauri R. Varadhachary, Robert A. Wolff, James L. Abbruzzese, Christopher H. Crane, Douglas B. Evans, Huamin Wang, Daniel E. Abbott, Jean-Nicolas Vauthey, Thomas A. Aloia, Jason B. Fleming, Matthew H. G. Katz, Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival, Journal of Gastrointestinal Surgery, 2014, 18, 1, 16

    CrossRef

  12. 12
    Edward J. Kim, Edgar Ben-Josef, Joseph M. Herman, Tanios Bekaii-Saab, Laura A. Dawson, Kent A. Griffith, Isaac R. Francis, Joel K. Greenson, Diane M. Simeone, Theodore S. Lawrence, Daniel Laheru, Christopher L. Wolfgang, Terence Williams, Mark Bloomston, Malcolm J. Moore, Alice Wei, Mark M. Zalupski, A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer, Cancer, 2013, 119, 15
  13. 13
    Matthew H. G. Katz, Robert Marsh, Joseph M. Herman, Qian Shi, Eric Collison, Alan P. Venook, Hedy L. Kindler, Steven R. Alberts, Philip Philip, Andrew M. Lowy, Peter W. T. Pisters, Mitchell C. Posner, Jordan D. Berlin, Syed A. Ahmad, Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design, Annals of Surgical Oncology, 2013, 20, 8, 2787

    CrossRef

  14. 14
    Chang Moo Kang, Ho Kyoung Hwang, Sung Hoon Choi, Woo Jung Lee, Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer, Surgical Oncology, 2013, 22, 2, 123

    CrossRef

  15. 15
    Pavlos Papavasiliou, Yun Shin Chun, John P. Hoffman, How to Define and Manage Borderline Resectable Pancreatic Cancer, Surgical Clinics of North America, 2013, 93, 3, 663

    CrossRef

  16. 16
    Paolo Passoni, Michele Reni, Giovanni M. Cattaneo, Najla Slim, Stefano Cereda, Gianpaolo Balzano, Renato Castoldi, Barbara Longobardi, Valentino Bettinardi, Luigi Gianolli, Simone Gusmini, Carlo Staudacher, Riccardo Calandrino, Nadia Di Muzio, Hypofractionated Image-Guided IMRT in Advanced Pancreatic Cancer With Simultaneous Integrated Boost to Infiltrated Vessels Concomitant With Capecitabine: A Phase I Study, International Journal of Radiation Oncology*Biology*Physics, 2013, 87, 5, 1000

    CrossRef

  17. 17
    Thomas B. Brunner, Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer: An Emerging Paradigm?, Current Oncology Reports, 2013, 15, 2, 162

    CrossRef

  18. 18
    V. Heinemann, M. Haas, S. Boeck, Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer, Annals of Oncology, 2013, 24, 10, 2484

    CrossRef

  19. 19
    Avani S. Dholakia, Amy Hacker-Prietz, Aaron T. Wild, Siva P. Raman, Laura D. Wood, Peng Huang, Daniel A. Laheru, Lei Zheng, Ana Jesus-Acosta, Dung T. Le, Richard Schulick, Barish Edil, Susannah Ellsworth, Timothy M. Pawlik, Christine A. Iacobuzio-Donahue, Ralph H. Hruban, John L. Cameron, Elliot K. Fishman, Christopher L. Wolfgang, Joseph M. Herman, Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships, Journal of Radiation Oncology, 2013, 2, 4, 413

    CrossRef

  20. 20
    Hirotada Kittaka, Hidenori Takahashi, Hiroaki Ohigashi, Kunihito Gotoh, Terumasa Yamada, Yasuhiko Tomita, Yoshihisa Hasegawa, Masahiko Yano, Osamu Ishikawa, Role of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Pathologic Response to Preoperative Chemoradiation Therapy in Patients With Resectable T3 Pancreatic Cancer, World Journal of Surgery, 2013, 37, 1, 169

    CrossRef

  21. 21
    Carolyn H Kim, Diane C Ling, Rodney E Wegner, John C Flickinger, Dwight E Heron, Herbert Zeh, Arthur J Moser, Steven A Burton, Stereotactic body radiotherapy in the treatment of Pancreatic Adenocarcinoma in elderly patients, Radiation Oncology, 2013, 8, 1, 240

    CrossRef

  22. 22
    Andrew Scott Paulson, Hop S. Tran Cao, Margaret A. Tempero, Andrew M. Lowy, Therapeutic Advances in Pancreatic Cancer, Gastroenterology, 2013, 144, 6, 1316

    CrossRef

  23. 23
    Amanda B. Cooper, Ching-Wei D. Tzeng, Matthew H. G. Katz, Treatment of Borderline Resectable Pancreatic Cancer, Current Treatment Options in Oncology, 2013, 14, 3, 293

    CrossRef

  24. 24
    Matthew H.G. Katz, Jeffrey E. Lee, Peter W.T. Pisters, Roman Skoracki, Eric Tamm, Jason B. Fleming, Retroperitoneal Dissection in Patients with Borderline Resectable Pancreatic Cancer: Operative Principles and Techniques, Journal of the American College of Surgeons, 2012, 215, 2, e11

    CrossRef